CIPHER PHARMACEUTICALS INC (CPH.CA) Fundamental Analysis & Valuation

TSX:CPH • CA17253X1050

Current stock price

18.51 CAD
+0.04 (+0.22%)
Last:

This CPH.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. CPH.CA Profitability Analysis

1.1 Basic Checks

  • In the past year CPH was profitable.
  • CPH had a positive operating cash flow in the past year.
  • CPH had positive earnings in each of the past 5 years.
  • Each year in the past 5 years CPH had a positive operating cash flow.
CPH.CA Yearly Net Income VS EBIT VS OCF VS FCFCPH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M -40M -60M

1.2 Ratios

  • CPH's Return On Assets of 17.46% is amongst the best of the industry. CPH outperforms 96.77% of its industry peers.
  • With an excellent Return On Equity value of 21.65%, CPH belongs to the best of the industry, outperforming 90.32% of the companies in the same industry.
  • CPH has a Return On Invested Capital of 9.24%. This is amongst the best in the industry. CPH outperforms 90.32% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for CPH is in line with the industry average of 9.14%.
  • The last Return On Invested Capital (9.24%) for CPH is above the 3 year average (7.38%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 17.46%
ROE 21.65%
ROIC 9.24%
ROA(3y)16.09%
ROA(5y)19.87%
ROE(3y)19.41%
ROE(5y)23.95%
ROIC(3y)7.38%
ROIC(5y)11.67%
CPH.CA Yearly ROA, ROE, ROICCPH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150 -200

1.3 Margins

  • CPH's Profit Margin of 54.17% is amongst the best of the industry. CPH outperforms 100.00% of its industry peers.
  • CPH's Profit Margin has improved in the last couple of years.
  • The Operating Margin of CPH (33.43%) is better than 100.00% of its industry peers.
  • In the last couple of years the Operating Margin of CPH has declined.
  • With an excellent Gross Margin value of 80.12%, CPH belongs to the best of the industry, outperforming 96.77% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CPH has remained more or less at the same level.
Industry RankSector Rank
OM 33.43%
PM (TTM) 54.17%
GM 80.12%
OM growth 3Y-14.47%
OM growth 5Y-9.91%
PM growth 3Y-25.08%
PM growth 5Y20.8%
GM growth 3Y-0.22%
GM growth 5Y-1.37%
CPH.CA Yearly Profit, Operating, Gross MarginsCPH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CPH.CA Health Analysis

2.1 Basic Checks

  • CPH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, CPH has less shares outstanding
  • CPH has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for CPH has been reduced compared to a year ago.
CPH.CA Yearly Shares OutstandingCPH.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
CPH.CA Yearly Total Debt VS Total AssetsCPH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • CPH has an Altman-Z score of 8.42. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of CPH (8.42) is better than 96.77% of its industry peers.
  • CPH has a debt to FCF ratio of 0.19. This is a very positive value and a sign of high solvency as it would only need 0.19 years to pay back of all of its debts.
  • CPH's Debt to FCF ratio of 0.19 is amongst the best of the industry. CPH outperforms 96.77% of its industry peers.
  • A Debt/Equity ratio of 0.04 indicates that CPH is not too dependend on debt financing.
  • CPH has a better Debt to Equity ratio (0.04) than 74.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.19
Altman-Z 8.42
ROIC/WACC1.07
WACC8.65%
CPH.CA Yearly LT Debt VS Equity VS FCFCPH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • CPH has a Current Ratio of 1.12. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.12, CPH is not doing good in the industry: 77.42% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.79 indicates that CPH may have some problems paying its short term obligations.
  • CPH has a Quick ratio of 0.79. This is in the lower half of the industry: CPH underperforms 67.74% of its industry peers.
  • The current and quick ratio evaluation for CPH is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 0.79
CPH.CA Yearly Current Assets VS Current LiabilitesCPH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. CPH.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 126.09% over the past year.
  • CPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 43.65% yearly.
  • Looking at the last year, CPH shows a very strong growth in Revenue. The Revenue has grown by 51.22%.
  • Measured over the past years, CPH shows a quite strong growth in Revenue. The Revenue has been growing by 18.48% on average per year.
EPS 1Y (TTM)126.09%
EPS 3Y0.69%
EPS 5Y43.65%
EPS Q2Q%292.31%
Revenue 1Y (TTM)51.22%
Revenue growth 3Y34.62%
Revenue growth 5Y18.48%
Sales Q2Q%3.35%

3.2 Future

  • The Earnings Per Share is expected to decrease by -1.30% on average over the next years.
  • Based on estimates for the next years, CPH will show a quite strong growth in Revenue. The Revenue will grow by 11.81% on average per year.
EPS Next Y-27.65%
EPS Next 2Y-3.95%
EPS Next 3Y-1.3%
EPS Next 5YN/A
Revenue Next Year5.16%
Revenue Next 2Y17.62%
Revenue Next 3Y11.81%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
CPH.CA Yearly Revenue VS EstimatesCPH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M
CPH.CA Yearly EPS VS EstimatesCPH.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

5

4. CPH.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 13.13, which indicates a correct valuation of CPH.
  • Compared to the rest of the industry, the Price/Earnings ratio of CPH indicates a rather cheap valuation: CPH is cheaper than 80.65% of the companies listed in the same industry.
  • CPH is valuated cheaply when we compare the Price/Earnings ratio to 27.15, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 18.09, the valuation of CPH can be described as rather expensive.
  • Based on the Price/Forward Earnings ratio, CPH is valued a bit cheaper than the industry average as 67.74% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 22.12. CPH is around the same levels.
Industry RankSector Rank
PE 13.13
Fwd PE 18.09
CPH.CA Price Earnings VS Forward Price EarningsCPH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • CPH's Enterprise Value to EBITDA is on the same level as the industry average.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CPH indicates a somewhat cheap valuation: CPH is cheaper than 77.42% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 11.65
EV/EBITDA 14.2
CPH.CA Per share dataCPH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • CPH has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.3
EPS Next 2Y-3.95%
EPS Next 3Y-1.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CPH.CA Dividend Analysis

5.1 Amount

  • No dividends for CPH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CPH.CA Fundamentals: All Metrics, Ratios and Statistics

CIPHER PHARMACEUTICALS INC

TSX:CPH (4/27/2026, 7:00:00 PM)

18.51

+0.04 (+0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners1.32%
Inst Owner ChangeN/A
Ins Owners3.97%
Ins Owner ChangeN/A
Market Cap467.93M
Revenue(TTM)50.45M
Net Income(TTM)27.33M
Analysts77.5
Price Target19.92 (7.62%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)146.06%
Min EPS beat(2)66.34%
Max EPS beat(2)225.78%
EPS beat(4)3
Avg EPS beat(4)80.27%
Min EPS beat(4)-7.18%
Max EPS beat(4)225.78%
EPS beat(8)5
Avg EPS beat(8)36.37%
EPS beat(12)9
Avg EPS beat(12)70.11%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-4.19%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)-2.37%
Revenue beat(4)1
Avg Revenue beat(4)-1.64%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)0.41%
Revenue beat(12)3
Avg Revenue beat(12)2.5%
Revenue beat(16)3
Avg Revenue beat(16)-1.15%
PT rev (1m)1.74%
PT rev (3m)1.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-32.5%
EPS NY rev (1m)25.21%
EPS NY rev (3m)91.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.72%
Revenue NY rev (1m)2.01%
Revenue NY rev (3m)-1.19%
Valuation
Industry RankSector Rank
PE 13.13
Fwd PE 18.09
P/S 6.82
P/FCF 11.65
P/OCF 11.57
P/B 2.73
P/tB 9.35
EV/EBITDA 14.2
EPS(TTM)1.41
EY7.62%
EPS(NY)1.02
Fwd EY5.53%
FCF(TTM)1.59
FCFY8.58%
OCF(TTM)1.6
OCFY8.64%
SpS2.71
BVpS6.79
TBVpS1.98
PEG (NY)N/A
PEG (5Y)0.3
Graham Number14.6788 (-20.7%)
Profitability
Industry RankSector Rank
ROA 17.46%
ROE 21.65%
ROCE 12.83%
ROIC 9.24%
ROICexc 9.8%
ROICexgc 35.19%
OM 33.43%
PM (TTM) 54.17%
GM 80.12%
FCFM 58.52%
ROA(3y)16.09%
ROA(5y)19.87%
ROE(3y)19.41%
ROE(5y)23.95%
ROIC(3y)7.38%
ROIC(5y)11.67%
ROICexc(3y)10.65%
ROICexc(5y)20.81%
ROICexgc(3y)28.57%
ROICexgc(5y)N/A
ROCE(3y)10.25%
ROCE(5y)16.21%
ROICexgc growth 3Y-8.89%
ROICexgc growth 5Y-26.34%
ROICexc growth 3Y-24.04%
ROICexc growth 5Y-22.32%
OM growth 3Y-14.47%
OM growth 5Y-9.91%
PM growth 3Y-25.08%
PM growth 5Y20.8%
GM growth 3Y-0.22%
GM growth 5Y-1.37%
F-Score8
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.19
Debt/EBITDA 0.22
Cap/Depr 2.78%
Cap/Sales 0.4%
Interest Coverage 250
Cash Conversion 123.36%
Profit Quality 108.04%
Current Ratio 1.12
Quick Ratio 0.79
Altman-Z 8.42
F-Score8
WACC8.65%
ROIC/WACC1.07
Cap/Depr(3y)669.05%
Cap/Depr(5y)403.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)126.09%
EPS 3Y0.69%
EPS 5Y43.65%
EPS Q2Q%292.31%
EPS Next Y-27.65%
EPS Next 2Y-3.95%
EPS Next 3Y-1.3%
EPS Next 5YN/A
Revenue 1Y (TTM)51.22%
Revenue growth 3Y34.62%
Revenue growth 5Y18.48%
Sales Q2Q%3.35%
Revenue Next Year5.16%
Revenue Next 2Y17.62%
Revenue Next 3Y11.81%
Revenue Next 5YN/A
EBIT growth 1Y114.98%
EBIT growth 3Y15.14%
EBIT growth 5Y6.74%
EBIT Next Year66.86%
EBIT Next 3Y28.71%
EBIT Next 5YN/A
FCF growth 1Y148.8%
FCF growth 3Y41.15%
FCF growth 5Y21.99%
OCF growth 1Y52.08%
OCF growth 3Y41.11%
OCF growth 5Y20.52%

CIPHER PHARMACEUTICALS INC / CPH.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?

ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.


Can you provide the valuation status for CIPHER PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 5 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.


Can you provide the profitability details for CIPHER PHARMACEUTICALS INC?

CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.


What is the earnings growth outlook for CIPHER PHARMACEUTICALS INC?

The Earnings per Share (EPS) of CIPHER PHARMACEUTICALS INC (CPH.CA) is expected to decline by -27.65% in the next year.